Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hahn

Showing results (1091-1100 of 1,198) with videos related to

Pageof 120
Sort By:
The Journal of Cell Biology|August 25, 2019
Software for lattice light-sheet imaging of FRET biosensors, illustrated with a new Rap1 biosensorEllen C O'Shaughnessy, Orrin J Stone, Paul K LaFosse, et al.
NIH Consensus and State-Of-The-Science Statements|September 29, 2009
NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 15, 2015
Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical useChristina Michailidi, Masamichi Hayashi, Sayantan Datta, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Journal of the National Cancer Institute|January 15, 2010
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Plos Computational Biology|September 17, 2024
Genome-wide association study between SARS-CoV-2 single nucleotide polymorphisms and virus copies during infectionsKe Li, Chrispin Chaguza, Julian Stamp, et al.
Breast Cancer Research and Treatment|May 24, 2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative studyDaneng Li, Linda M McCall, Olwen M Hahn, et al.
Leukemia|June 2, 2017
Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signalingM Hahn, J-P Bürckert, C A Luttenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2019
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, et al.
Cancer|June 22, 2021
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancerFilipa Lynce, Matthew J Blackburn, Rebecca Zhuo, et al.
Pageof 120

Showing results (1091-1100 of 1,198) with videos related to

Sort By:
Pageof 120
The Journal of Cell Biology|August 25, 2019
Software for lattice light-sheet imaging of FRET biosensors, illustrated with a new Rap1 biosensorEllen C O'Shaughnessy, Orrin J Stone, Paul K LaFosse, et al.
NIH Consensus and State-Of-The-Science Statements|September 29, 2009
NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS)Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 15, 2015
Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical useChristina Michailidi, Masamichi Hayashi, Sayantan Datta, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Journal of the National Cancer Institute|January 15, 2010
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009Carmen J Allegra, Denise R Aberle, Pamela Ganschow, et al.
Plos Computational Biology|September 17, 2024
Genome-wide association study between SARS-CoV-2 single nucleotide polymorphisms and virus copies during infectionsKe Li, Chrispin Chaguza, Julian Stamp, et al.
Breast Cancer Research and Treatment|May 24, 2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative studyDaneng Li, Linda M McCall, Olwen M Hahn, et al.
Leukemia|June 2, 2017
Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signalingM Hahn, J-P Bürckert, C A Luttenberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2019
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 TherapyJonathan E Rosenberg, Peter H O'Donnell, Arjun V Balar, et al.
Cancer|June 22, 2021
Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancerFilipa Lynce, Matthew J Blackburn, Rebecca Zhuo, et al.
Pageof 120